• 제목/요약/키워드: tumor tissues

검색결과 1,042건 처리시간 0.028초

외상에 의하여 심장눌림증을 유발한 종격동 양성낭기형종 (Benign Mediastinal Cystic Teratoma Complicated by Cardiac Tamponade due to Trauma)

  • 최주원;김용인
    • Journal of Chest Surgery
    • /
    • 제39권9호
    • /
    • pp.729-732
    • /
    • 2006
  • 외상에 의하여 심장눌림증을 유발한 종격동 양성낭기형종 종격동 기형종은 전체 종격동 종양의 $8\sim13%$ 빈도로 발생하며, 대부분 우연히 발견되지만 드물게 심낭 천공이 발생하여 심장눌림증을 유발하거나, 흉막삼출액을 고이게 한다. 본 증례에서는 전흉벽 타박상을 받은 여자 환자에게서 심장눌림증이 발생하였고, 응급 방사선검사에서 종격전부 종양이 확인되었으며 심장막천자술을 받은 후 활력징후가 회복되어 추후 수술적 절제술로 종양을 적출하였다. 조직검사에서 피지선, 성숙 지방종, 위장관점막, 호흡기도 점막 및 췌장의 조직 등으로 구성된 낭포성 구조물로 관찰되어 양성 낭기형종으로 판정되었다.

전종격동에 발생한 악성 섬유 조직구종 -1예 보고- (Malignant Fibrous Histiocytoma of the Anterior Mediastinum -A case report -)

  • 김혁;노선균;강정호;정원상;박문향;김영학
    • Journal of Chest Surgery
    • /
    • 제39권10호
    • /
    • pp.802-804
    • /
    • 2006
  • 악성 섬유 조직구종은 사지나 후복막의 연부조직에 주로 발생하는 종양으로 종격동에 발생하는 경우는 극히 드물다. 환자는 71세 남자 환자로 전종격동에 발생한 원발성 종양에 대해 종양 제거술을 시행하였고 조직학적으로 악성 섬유 조직구종으로 진단되었다.

두피에 발생한 악성말초신경초종양 (Malignant Peripheral Nerve Sheath Tumor of Scalp)

  • 이기영;배준성;전영준;이희정;김영진
    • Archives of Plastic Surgery
    • /
    • 제34권4호
    • /
    • pp.495-497
    • /
    • 2007
  • Purpose: Malignant peripheral nerve sheath tumors (MPNSTs) are rare neoplasms, usually arising from somatic soft tissues or peripheral nerves. Primary MPNST of the scalp is extremely rare. The case is being reported for its rarity. Methods: A 53-year-old female was presented with a scalp mass on vertex area. The tumor was localized in scalp skin and did not invade underlying periosteum or skull and treated with complete surgical excision followed by adjuvant chemotherapy and radiotherapy. Results: Histologically, the tumor showed malignant spindle cells with focal S-100 positivity on immunohistochemistry and a diagnosis of MPNST was made. Conclusion: Authors experienced a rare case of primary scalp MPNST and report the case.

Novel biological strategies to enhance the radiation therapeutic ratio

  • Kim, Jae Ho;Jenrow, Kenneth A.;Brown, Stephen L.
    • Radiation Oncology Journal
    • /
    • 제36권3호
    • /
    • pp.172-181
    • /
    • 2018
  • Successful anticancer strategies require a differential response between tumor and normal tissue (i.e., a therapeutic ratio). In fact, improving the effectiveness of a cancer therapeutic is of no clinical value in the absence of a significant increase in the differential response between tumor and normal tissue. Although radiation dose escalation with the use of intensity modulated radiation therapy has permitted the maximum tolerable dose for most locally advanced cancers, improvements in tumor control without damaging normal adjacent tissues are needed. As a means of increasing the therapeutic ratio, several new approaches are under development. Drugs targeting signal transduction pathways in cancer progression and more recently, immunotherapeutics targeting specific immune cell subsets have entered the clinic with promising early results. Radiobiological research is underway to address pressing questions as to the dose per fraction, irradiated tumor volume and time sequence of the drug administration. To exploit these exciting novel strategies, a better understanding is needed of the cellular and molecular pathways responsible for both cancer and normal tissue and organ response, including the role of radiation-induced accelerated senescence. This review will highlight the current understanding of promising biologically targeted therapies to enhance the radiation therapeutic ratio.

비강 내 발생한 고립성 섬유종 1예 (A Case of Solitary Fibrous Tumor in Nasal Cavity)

  • 이명준;박병후;조재만;김용완
    • 임상이비인후과
    • /
    • 제29권2호
    • /
    • pp.254-258
    • /
    • 2018
  • The solitary fibrous tumor (SFT) is a mesenchymal neoplasm that is described as spindle-shaped tumor cells on a collagenous background originating from pleural tissues. Recently, extrapleural SFT has been reported in nearly all sites, including the sublingual gland, parotid gland, nasal cavity and paranasal sinuses. Complete surgical excision is primary treatment for SFT, but diagnosing SFT is not often made until immunohistochemical evaluation after surgical resection. We report that the patient, 45-year-old male, was considered as a case of inflammation polyp arising from left nasal cavity with initial biopsy, however, it has turned out to be SFT after surgical treatment.

하악지 영역에 발생한 미분화성 다형성 육종: 수술 후 재발한 증례 (Undifferentiated Pleomorphic Sarcoma in the Mandibular Ramus and Post-Operative Recurrence: A Case Report)

  • 안재명;장승일;홍종락;팽준영
    • 대한구강악안면병리학회지
    • /
    • 제42권5호
    • /
    • pp.135-143
    • /
    • 2018
  • Undifferentiated pleomorphic sarcoma (UPS) in the mandible region is a rare malignant neoplasm. We encountered the case of a patient who had been diagnosed with deep benign fibrous histiocytoma (DBFH) prior to surgery, but the final biopsy revealed the presence of tumor tissues in the resected margin, which indicated a UPS. Therefore, radiotherapy was conducted post-operatively, but the tumor recurred approximately 3 years later and a second surgery was performed. The difference between the initial and final diagnoses was considered to be due to the characteristics of the tumor, as it involved both benign and malignant components. DBFH and UPS can occur in young women. DBFH can transform to a malignancy and UPS may also appear as a benign tumor during early biopsy. Hence, attention should be paid to diagnosis and treatment methods, and ongoing close observation is required.

Bioinformatical Analysis of Messenger RNA and MicroRNA on Canine Splenic Tumors Based on Malignancy and Biopsy Sites

  • Eunpyo Kim;Giup Jang;Jin-Wook Kim;Wan-Hee Kim;Geon-A Kim
    • 한국임상수의학회지
    • /
    • 제40권2호
    • /
    • pp.164-174
    • /
    • 2023
  • Canine splenic tumors (STs) are commonly diagnosed during imaging examinations, such as in X-ray and ultrasonography examinations, suggesting their higher prevalence, especially in older dogs. Despite this high prevalence, there are no effective treatment options for STs because of the difficulties in determining therapeutic targets. However, recently, the importance of microRNAs (miRNAs) has evolved owing to their ambivalent characteristics. Biomarkers and novel therapies using miRNAs have been well-studied in human cancer research compared to canine research, except for mammary gland tumors. Therefore, this study aimed to comparatively analyze miRNA expression profiles according to malignancy and biopsy sites to identify novel therapeutic and diagnostic targets. Tissue samples were collected directly from splenic tumor masses and immersed in RNAlater solution for further analysis. To investigate differentially expressed genes (DEGs) between tumor and normal tissues, we used RNA-seq and miRNA microarray analysis. Then, functional analysis based on DEGs was conducted to sort tumor-related DEGs. We found that cfa-miR-150 was upregulated in benign tumors, whereas cfa-miR-134 was upregulated in malignant tumors. Despite limited information on canine miRNAs, we identified two potential biomarkers for the differential diagnosis of STs.

Down-regulation of Protease-activated Receptor 4 in Lung Adenocarcinoma is Associated with a More Aggressive Phenotype

  • Jiang, Ping;Yu, Guo-Yu;Zhang, Yong;Xiang, Yang;Hua, Hai-Rong;Bian, Li;Wang, Chun-Yan;Lee, Wen-Hui;Zhang, Yun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권6호
    • /
    • pp.3793-3798
    • /
    • 2013
  • The role of protease-activated receptors (PARs) in lung tumors is controversial. Although PAR4 is preferentially expressed in human lung tissues, its possible significance in lung cancer has not been defined. The studies reported herein used a combination of clinical observations and molecular methods. Surgically resected lung adenocarcinomas and associated adjacent normal lung tissues were collected and BEAS-2B and NCI-H157 cell lines were grown in tissue culture. PAR4 expression was evaluated by RT-PCR, RT-qPCR, Western blotting and immunohistochemistry analysis. The results showed that PAR4 mRNA expression was generally decreased in lung adenocarcinoma tissues as compared with matched noncancerous tissues (67.7%) and was associated with poor differentiation (p=0.017) and metastasis (p=0.04). Western blotting and immunohistochemical analysis also showed that PAR4 protein levels were mostly decreased in lung adenocarcinoma tissues (61.3%), and were also associated with poor differentiation (p=0.035) and clinical stage (p=0.027). Moreover, PAR4 expression was decreased in NCI-H157 cells as compared with BEAS-2B cells. In conclusion, PAR4 expression is significantly decreased in lung adenocarcinoma, and down-regulation of PAR4 is associated with a more clinically aggressive phenotype. PAR4 may acts as a tumor suppressor in lung adenocarcinoma.

유방암 세포(EMT6) 이식 마우스에서 녹차폴리페놀 음용이 시스플라틴의 암 조직 성장 억제에 미치는 영향 (Effects of Dietary Tea Polyphenol on Tumor Growth Inhibition by Cisplatin in EMT6 Breast Tumor-bearing Mice)

  • 이병래;조정일;박평심
    • 한국식품영양과학회지
    • /
    • 제43권1호
    • /
    • pp.47-54
    • /
    • 2014
  • 본 연구는 녹차폴리페놀이 시스플라틴의 항암작용과 신장 독성에 미치는 영향을 유방암 세포(EMT6)와 암세포 이식마우스를 이용하여 in vitro와 in vivo 실험으로 관찰하였다. 배양한 EMT6 세포에서 녹차폴리페놀은 시스플라틴에 의한 세포 독성을 증가시켰다. 마우스에 EMT6 세포를 주사하여 유발된 종양의 크기가 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 작았고, 종양조직 p53와 caspase-3 활성화가 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 높았으며, 신장 GGT와 AP 활성은 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 높았고, 신장 조직학적 소견에서 신세뇨관 확장과 괴사가 시스플라틴군(CP)보다 시스플라틴+녹차폴리페놀군(CP+GTP)에서 유의하게 낮았다. 이상의 결과 녹차폴리페놀은 EMT6 유방암 세포를 이용한 in vitro 및 in vivo 실험에서 시스플라틴의 항암작용을 증강시키면서 신장에 대한 독성 부작용은 감소시키는 효과가 있는 것으로 추측된다. 녹차폴리페놀의 시스플라틴 항암작용 증강과 신장 독성 억제 및 감소 효과는 시스플라틴에 의한 암 치료 시 화학요법제의 보조제로서 이용가치가 있는 것으로 생각되며, 항암화학요법제에 대한 보조제로의 개발을 위해서는 대규모 동물실험을 통한 효과 입증 및 부작용에 대한 실험과 임상연구가 뒷받침되어야 할 것으로 사료된다.

Active Immunization Study of Colon Cancer Derived 1-8D Peptide in HHD Mice

  • Jung, Hun-Soon;Ahn, In-Sook;Do, Hyung-Ki;Lemonnier, Francois A.;Song, Kuk-Hyun;Do, Myoung-Sool
    • IMMUNE NETWORK
    • /
    • 제5권3호
    • /
    • pp.157-162
    • /
    • 2005
  • Background: 1-8D gene is a member of human 1-8 interferon inducible gene family and was shown to be overexpressed in fresh colon cancer tissues. Three peptides 1-6, 3-5 and 3-7 derived from human 1-8D gene were shown to have immunogenicity against colon cancer. Methods: To study tumor immunotherapy, of three peptides we established an active immunization model using HHD mice. $D^{b-/-}{\times}{\beta}2$ microglobulin $({\beta}2m)$ null mice transgenic for a chimeric HLA-$A2.1/D^{b-}\;{\beta}2m$ single chain (HHD mice) were challenged with B16/HHD/1-8D tumor cells and were immunized with irradiated peptide-loaded RMA- S/HHD/B7.1 transfectants. In therapy model tumor growth was retarded in HHD mice that were injected with 3-5 peptide-loaded RMA-S/HHD/B7.1. In survival test vaccination with 1-8D-derived peptide protects HHD mice from tumor progression after tumor challenge. Results: These studies show that peptide 3-5 derived from 1-8D gene can be the most effective candidate for the vaccine of immunotherapy against colon cancer and highlight 1-8D gene as putative colon carcinoma associated antigens. Conclusion: We demonstrated that RMA-S/HHD/ B7.1 loaded with 1-8D peptides, especially 3-5, immunization generates potent antitumor immunity against tumor cells in HHD mice and designed active immunization as proper immunotherapeutic protocols.